BORTEZOMIB (bortezomib) by Fresenius Kabi is chymotrypsin-like activity of the 26s proteasome in mammalian cells. First approved in 2017.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
Bortezomib is a small-molecule proteasome inhibitor that blocks the chymotrypsin-like activity of the 26S proteasome, preventing degradation of ubiquitinated proteins and triggering cancer cell death. It is primarily used to treat multiple myeloma and other hematologic malignancies. The drug works by disrupting cellular homeostasis through inhibition of the ubiquitin-proteasome pathway, leading to apoptosis in cancer cells.
Peak lifecycle stage indicates stable mature revenues with established market presence, supporting established commercial and medical affairs teams.
chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Worked on BORTEZOMIB at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moBortezomib offers stable career opportunities in a mature, established product with peak lifecycle revenues and established market position. Roles are primarily concentrated in commercial execution, medical education, and market access rather than development or innovation.